Literature DB >> 26174440

Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.

D Cárdenas1, G Vélez1, A Orfao2, M V Herrera3, J Solano3, M Olaya4, A M Uribe4, C Saavedra5, M Duarte6, M Rodríguez6, M López7, S Fiorentino1, S Quijano1.   

Abstract

Epstein-Barr virus (EBV) is a persistent virus with oncogenic capacity that has been implicated in the development of aggressive B cell lymphomas, primarily in immunosuppressed individuals, although it can be present in immunocompetent individuals. Changes in the function and clonal diversity of T lymphocytes might be implied by viral persistence and lymphoma development. The aim of the present study was to evaluate the frequency, phenotype, function and clonotypical distribution of EBV-specific T cells after peripheral blood stimulation with a virus lysate in newly diagnosed patients with diffuse large B cell lymphoma (DLBCL) aged more than 50 years without prior histories of clinical immunosuppression compared with healthy controls. Our results showed impaired EBV-specific immune responses among DLBCL patients that were associated primarily with decreased numbers of central and effector memory CD8(+) T lymphocytes. In contrast to healthy controls, only a minority of the patients showed CD4(+)/tumour necrosis factor (TNF)-α(+) T cells expressing T cell receptor (TCR)-Vβ17 and CD8(+)/TNF-α(+) T cells with TCR-Vβ5·2, Vβ9 and Vβ18 in response to EBV. Notably, the production of TNF-α was undetectable among TCR-Vβ5·3(+), Vβ11(+), Vβ12(+), Vβ16(+) and Vβ23(+) CD8(+) T cells. In addition, we observed decreased numbers of CD4(+)/TNF-α(+) and CD8(+)/TNF-α(+), CD8(+)/interleukin (IL)-2(+) and CD8(+)/TNF-α(+)/IL-2(+) T lymphocytes in the absence of T cells capable of producing TNF-α, IL-2 and IFN-γ after EBV stimulation simultaneously. Moreover, DLBCL patients displayed higher IL-10 levels both under baseline conditions and after EBV stimulation. These findings were also observed in patients with positive EBV viral loads. Prospective studies including a large number of patients are needed to confirm these findings.
© 2015 British Society for Immunology.

Entities:  

Keywords:  EBV; TCR-Vβ repertoire; diffuse large B cell lymphoma; memory and effector T lymphocytes; soluble cytokines

Mesh:

Substances:

Year:  2015        PMID: 26174440      PMCID: PMC4608507          DOI: 10.1111/cei.12682

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  56 in total

1.  Contemporaneous fluctuations in T cell responses to persistent herpes virus infections.

Authors:  Tania Crough; Jacqueline M Burrows; Chrysa Fazou; Susan Walker; Miles P Davenport; Rajiv Khanna
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

Review 2.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Authors:  George Makedonas; Michael R Betts
Journal:  Springer Semin Immunopathol       Date:  2006-08-25

3.  Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.

Authors:  Emanuela M Iancu; Patricia Corthesy; Petra Baumgaertner; Estelle Devevre; Verena Voelter; Pedro Romero; Daniel E Speiser; Nathalie Rufer
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

4.  Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708-712.

Authors:  Federica Sallusto; Danielle Lenig; Reinhold Förster; Martin Lipp; Antonio Lanzavecchia
Journal:  J Immunol       Date:  2014-02-01       Impact factor: 5.422

5.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 6.  EBV the prototypical human tumor virus--just how bad is it?

Authors:  David A Thorley-Lawson
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

7.  Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.

Authors:  Erwan Piriou; Karel van Dort; Nening M Nanlohy; Marinus H J van Oers; Frank Miedema; Debbie van Baarle
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

Review 8.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

Review 9.  Spectrum of Epstein-Barr virus-associated diseases.

Authors:  J L Kutok; F Wang
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

Review 10.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

View more
  9 in total

Review 1.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

2.  bcRep: R Package for Comprehensive Analysis of B Cell Receptor Repertoire Data.

Authors:  Julia Bischof; Saleh M Ibrahim
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

Review 3.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

4.  Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection.

Authors:  Elham Khatamzas; Markus H Antwerpen; Maximilian Muenchhoff; Andreas Moosmann; Alexandra Rehn; Alexander Graf; Johannes Christian Hellmuth; Alexandra Hollaus; Anne-Wiebe Mohr; Erik Gaitzsch; Tobias Weiglein; Enrico Georgi; Clemens Scherer; Stephanie-Susanne Stecher; Stefanie Gruetzner; Helmut Blum; Stefan Krebs; Anna Reischer; Alexandra Leutbecher; Marion Subklewe; Andrea Dick; Sabine Zange; Philipp Girl; Katharina Müller; Oliver Weigert; Karl-Peter Hopfner; Hans-Joachim Stemmler; Michael von Bergwelt-Baildon; Oliver T Keppler; Roman Wölfel
Journal:  Nat Commun       Date:  2022-09-23       Impact factor: 17.694

5.  Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact.

Authors:  Melina Cohen; Aldana G Vistarop; Fuad Huaman; Marina Narbaitz; Fernanda Metrebian; Elena De Matteo; María V Preciado; Paola A Chabay
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

Review 6.  Epstein-Barr virus-associated lymphomas.

Authors:  Claire Shannon-Lowe; Alan B Rickinson; Andrew I Bell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

7.  Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers.

Authors:  David Egg; Charlotte Schwab; Annemarie Gabrysch; Peter D Arkwright; Edmund Cheesman; Lisa Giulino-Roth; Olaf Neth; Scott Snapper; Satoshi Okada; Michel Moutschen; Philippe Delvenne; Ann-Christin Pecher; Daniel Wolff; Yae-Jean Kim; Suranjith Seneviratne; Kyoung-Mee Kim; Ji-Man Kang; Samar Ojaimi; Catriona McLean; Klaus Warnatz; Maximilian Seidl; Bodo Grimbacher
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

8.  Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV+ Patients.

Authors:  Diana M Hernández; Sandra Valderrama; Sandra Gualtero; Catalina Hernández; Marcos López; Maria Victoria Herrera; Julio Solano; Susana Fiorentino; Sandra Quijano
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

Review 9.  Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma.

Authors:  Paola Chabay
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.